NASDAQ:GNFT

Genfit - GNFT Stock Forecast, Price & News

$4.04

+0.24 (+6.32%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.80
▼
$4.08
50-Day Range: $3.65
▼
$4.86
52-Week Range: $3.01
▼
$6.38

Volume: 31,871 shs
Average Volume: 30,168 shs
Market Capitalization: $201.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Genfit MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 122.8% Upside
$9.00 Price Target
Short Interest: Healthy
0.36% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.87
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.90) to ($0.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

784th out of 1,087 stocks

Biological Products, Except Diagnostic Industry

129th out of 169 stocks

3.5

Analyst's Opinion

Consensus Rating
Genfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Genfit has a forecasted upside of 122.8% from its current price of $4.04.
Amount of Analyst Coverage
Genfit has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.36% of the float of Genfit has been sold short.
Short Interest Ratio / Days to Cover
Genfit has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Genfit has recently increased by 13.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Genfit does not currently pay a dividend.
Dividend Growth
Genfit does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GNFT.

2.7

News and Social Media Coverage

News Sentiment
Genfit has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Genfit this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for GNFT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
2 people have added Genfit to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genfit insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 4.16% of the stock of Genfit is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Genfit are expected to grow in the coming year, from ($0.90) to ($0.10) per share.
Price to Book Value per Share Ratio
Genfit has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Genfit (NASDAQ:GNFT) Stock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

September 30, 2022 | globenewswire.com

GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis - GlobeNewswire

September 28, 2022 | globenewswire.com

GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update - GlobeNewswire

September 19, 2022 | finance.yahoo.com

Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases - Yahoo Finance

September 19, 2022 | finance.yahoo.com

Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases

September 19, 2022 | uk.finance.yahoo.com

Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial - Yahoo Finance UK

September 19, 2022 | seekingalpha.com

Genfit to acquire Swiss-based Versantis in liver diseases biotech (NASDAQ:GNFT) - Seeking Alpha

September 19, 2022 | globenewswire.com

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases - GlobeNewswire

September 13, 2022 | benzinga.com

Genfit (NASDAQ:GNFT) – GENFIT Announces FDA Has Granted Orphan Drug Designation To GNS5611, For The Treat - Benzinga

September 13, 2022 | globenewswire.com

FDA Grants GENFIT's GNS561 Orphan Drug Designation for the - GlobeNewswire

September 12, 2022 | streetinsider.com

GenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe - StreetInsider.com

September 7, 2022 | seekingalpha.com

Genfit S.A.: A 'Sum Of The Parts' Story (NASDAQ:GNFT) - Seeking Alpha

September 4, 2022 | reuters.com

GNFT.PA - Genfit SA | Stock Price & Latest News | Reuters

August 19, 2022 | benzinga.com

Analyzing Genfit's Short Interest - Benzinga

August 18, 2022 | streetinsider.com

SELLAS Life Sciences (SLS) Appoints Katherine Bach Kalin to its Board - StreetInsider.com

August 16, 2022 | finance.yahoo.com

SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors - Yahoo Finance

July 29, 2022 | businesswire.com

Non-alcoholic Steatohepatitis Biomarkers Market Analysis: Hepatic Fibrosis, Serum, Oxidative Stress, Apoptosis - Global Forecast to 2029 - ResearchAndMarkets.com - Business Wire

July 8, 2022 | barrons.com

Intercept Will Ask Yet Again for FDA to Approve Its NASH Drug - Barron's

July 8, 2022 | rttnews.com

Pre-market Movers: DBD, SRG, ISIG, UPST, CSSE… - RTTNews

June 22, 2022 | globenewswire.com

Nonalcoholic Steatohepatitis Therapeutics Market Expands with Rising Cases of Obesity and Diabetes, States TMR Report - GlobeNewswire

June 14, 2022 | seekingalpha.com

Gelesis, Entrada top healthcare gainers; Outset Medical, Arcellx lead losers' pack - Seeking Alpha

June 8, 2022 | nasdaq.com

Pre-market Movers: XCUR, CYRN, EFOI, NVAX, AERC… - Nasdaq

May 25, 2022 | finance.yahoo.com

GENFIT: May 25, 2022 Combined Shareholders Meeting results - Yahoo Finance

May 12, 2022 | finance.yahoo.com

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) - Yahoo Finance

May 11, 2022 | globenewswire.com

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) - GlobeNewswire

May 4, 2022 | globenewswire.com

Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, - GlobeNewswire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Company Calendar

Today: 10/04/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GNFT
CUSIP: N/A
CIK: 1757064
Web: www.genfit.com
Phone: (332) 016-4000
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +122.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 6.33
Quick Ratio: 6.33

Sales & Book Value

Annual Sales: $101.25 million
Price / Sales: 1.99
Cash Flow: $1.77 per share
Price / Cash Flow: 2.28
Book Value: $2.83 per share
Price / Book: 1.43

Miscellaneous

Outstanding Shares: 49,815,000
Free Float: N/A
Market Cap: $201.25 million
Optionable: Not Optionable
Beta: 1.44

Key Executives

Mr. Jean-Francois Mouney (Age 67)
Co-Founder & Chairman
Comp: $322.08k

Mr. M. Pascal Prigent (Age 54)
Chief Exec. Officer
Comp: $488.07k

Prof. Bart Staels (Age 59)
Co-Founder & Chairman of the Scientific Advisory Board

Mr. Thomas Baetz (Age 48)
Chief Financial Officer

Mr. Pascal Caisey (Age 54)
Chief Operating Officer

Dr. Dean W. Hum Ph.D. (Age 60)
Chief Scientific Officer

Mr. Laurent Lannoo (Age 52)
Corp. Sec. & Director of Legal Affairs

Ms. Stefanie Magner (Age 41)
Chief Compliance Officer & VP of International Legal Affairs

Ms. Emilie Desodt (Age 39)
Vice-Pres of HR

Mr. Jean-Christophe Marcoux (Age 45)
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GNFT Stock - Frequently Asked Questions

Should I buy or sell Genfit stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNFT shares.
View GNFT analyst ratings or view top-rated stocks.
What is Genfit's stock price forecast for 2022?: 3 equities research analysts have issued 1 year target prices for Genfit's stock. Their GNFT share price forecasts range from $8.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 122.8% from the stock's current price.
View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts.
How have GNFT shares performed in 2022?: Genfit's stock was trading at $5.00 at the start of the year. Since then, GNFT stock has decreased by 19.2% and is now trading at $4.04.
View the best growth stocks for 2022 here.
What is Jean-François Mouney's approval rating as Genfit's CEO?: 3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Genfit own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN).

When did Genfit IPO?: (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.
What is Genfit's stock symbol?: Genfit trades on the NASDAQ under the ticker symbol "GNFT."
How do I buy shares of Genfit?: Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Genfit's stock price today?: One share of GNFT stock can currently be purchased for approximately $4.04.
How much money does Genfit make?: Genfit (NASDAQ:GNFT) has a market capitalization of $201.25 million and generates $101.25 million in revenue each year.
How many employees does Genfit have?: The company employs 122 workers across the globe.
How can I contact Genfit?: Genfit's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The official website for the company is www.genfit.com. The company can be reached via phone at (332) 016-4000 or via email at investors@genfit.com.

This page (NASDAQ:GNFT) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genfit - GNFT Stock Forecast, Price & News

Genfit MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows